AAV Capsid Serotype Selection for CNS Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering therapeutic agents to the central nervous system (CNS) are inefficient and lack optimal distribution, leading to suboptimal treatment of CNS disorders, particularly in Friedreich's Ataxia, where the expression of therapeutic transgenes needs to be spatially and temporally precise to achieve desired ameliorative effects.
Innovation Solution
An adeno-associated virus (AAV) particle comprising a capsid and a viral genome that encodes Frataxin and microRNA binding sites, specifically designed to target the CNS, is administered intravenously or intracerebrally to ensure effective delivery and expression of Frataxin, addressing the inefficiencies in existing delivery methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If adeno-associated virus (AAV) is used to deliver therapeutic agents to the central nervous system, then widespread distribution of delivered genes in the CNS and PNS is achieved, but inefficiency in delivery and lack of optimal distribution occur
Solution Approach 1:
The patent applies local quality by selecting specific AAV capsid serotypes (such as AAV9, AAVrh10, AAVrh74) that have demonstrated preferential tropism for nervous system tissues. This allows the therapeutic payload to be delivered with enhanced efficiency to specific target regions (CNS and PNS) while maintaining widespread distribution, resolving the contradiction between distribution quantity and delivery efficiency through serotype-specific optimization
Solution Approach 2:
The patent employs parameter changes by modifying the AAV capsid structure through pseudotyping with different serotypes and optimizing the viral genome composition (including self-complementary vs. single-stranded DNA, promoter selection, and microRNA binding sites). These parameter modifications enhance transduction efficiency and tissue-specific targeting, thereby improving delivery productivity while maintaining widespread distribution capability
2Area of stationary object
If therapeutic transgenes are delivered to achieve widespread distribution in CNS and PNS, then coverage of heterogeneous tissues is improved, but spatial and temporal precision of expression is reduced
Solution Approach 1:
The patent implements local quality by incorporating tissue-specific and cell-type-specific promoter elements (such as neuronal promoters, glial promoters) into the AAV viral genome. These promoters enable spatially precise expression of the therapeutic transgene within specific cell types (neurons, oligodendrocytes, astrocytes, microglia) while maintaining widespread distribution across heterogeneous CNS and PNS tissues. Additionally, microRNA binding sites are designed to provide cell-type-specific post-transcriptional regulation, further refining spatial expression precision
Solution Approach 2:
The patent applies preliminary action by pre-engineering the AAV viral genome with optimized regulatory elements (promoters, enhancers, microRNA binding sites) before delivery. This preliminary design ensures that upon delivery to the nervous system, the therapeutic transgene is expressed with the desired spatial and temporal precision from the outset, eliminating the need for post-delivery adjustment and achieving both widespread coverage and precise expression control
Data Source
AI summary
Described herein are compositions and methods for treating Friedreich's Ataxia (FA) using adeno-associated virus (AAV) to deliver therapeutics agents.